These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 2774606)

  • 1. The size of lesions, or point counting as a step toward the solution of the PASI problem.
    Bahmer F
    Arch Dermatol; 1989 Sep; 125(9):1282-3. PubMed ID: 2774606
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
    Yoon HS; Youn JI
    J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients.
    Louden BA; Pearce DJ; Lang W; Feldman SR
    Dermatol Online J; 2004 Oct; 10(2):7. PubMed ID: 15530297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
    Jacobson CC; Kimball AB
    Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index.
    Berth-Jones J; Thompson J; Papp K;
    Br J Dermatol; 2008 Aug; 159(2):407-12. PubMed ID: 18565187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of machine vision to assess involved surface in patients with psoriasis.
    Savolainen L; Kontinen J; Röning J; Oikarinen A
    Br J Dermatol; 1997 Sep; 137(3):395-400. PubMed ID: 9349336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea.
    Harari M; Novack L; Barth J; David M; Friger M; Moses SW
    Int J Dermatol; 2007 Oct; 46(10):1087-91. PubMed ID: 17910722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.
    Berth-Jones J; Grotzinger K; Rainville C; Pham B; Huang J; Daly S; Herdman M; Firth P; Hotchkiss K
    Br J Dermatol; 2006 Oct; 155(4):707-13. PubMed ID: 16965419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
    Carlin CS; Feldman SR; Krueger JG; Menter A; Krueger GG
    J Am Acad Dermatol; 2004 Jun; 50(6):859-66. PubMed ID: 15153885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of facial psoriasis based on the distributions of facial lesions.
    Woo SM; Choi JW; Yoon HS; Jo SJ; Youn JI
    J Am Acad Dermatol; 2008 Jun; 58(6):959-63. PubMed ID: 18359126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1.
    Flisiak I; Myśliwiec H; Chodynicka B
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):418-21. PubMed ID: 15987285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocytapheresis in the treatment of psoriasis vulgaris.
    Liumbruno GM; Centoni PE; Molfettini P; Ceretelli S; Ceccarini M; Bachini L; Pomponi A; Bagnoni G; Vitolo M; Eberle O; Biondi A; Sodini ML
    J Clin Apher; 2006 Oct; 21(3):158-64. PubMed ID: 16425186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
    Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E
    Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
    Skov L; Kragballe K; Zachariae C; Obitz ER; Holm EA; Jemec GB; Sølvsten H; Ibsen HH; Knudsen L; Jensen P; Petersen JH; Menné T; Baadsgaard O
    Arch Dermatol; 2003 Nov; 139(11):1433-9. PubMed ID: 14623703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study.
    Ehrlich A; Booher S; Becerra Y; Borris DL; Figg WD; Turner ML; Blauvelt A
    J Am Acad Dermatol; 2004 Apr; 50(4):533-40. PubMed ID: 15034502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. True scale representation in photographing the human figure.
    Shemilt J
    J Audiov Media Med; 1985 Oct; 8(4):140-2. PubMed ID: 4067191
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical aspects of psoriasis].
    Beylot C
    Rev Prat; 2004 Jan; 54(1):19-27. PubMed ID: 15049595
    [No Abstract]   [Full Text] [Related]  

  • 20. In situ characterization and counting of mononuclear cells in lesions of different clinical forms of psoriasis.
    Bjerke JR
    Acta Derm Venereol; 1982; 62(2):93-100. PubMed ID: 6179355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.